From the clinical and laboratory documents of the patients with multiple myeloma, the authors had drawn some conclusions. Most patients are from 45 to 59 years old (60%). The first clinical symptoms often seen are bone pain and anemia. Plasma cell is proliferated (in 93% of cases) and dominates the growth of other blood cells (erythrocytes, leukocytes and thrombocytes). The immuno-electro phoresis X-rays... were found. Bence-Jones protein in the urine was positive in 27% of cases
Multiple Myeloma ; X-Rays ; diagnosis

A retrospective investigation was carried out during 1991-96 year period on 44 MM patients (27 men and 17 women of the mean age of 52.4 ranged 20-70, admitted to Bach Mai Hospital) diagnosed with R.A. Kyle's critera to review clinic symtoms and laboratory findings. The earliest signes were bone pain (72.3%) including low back pain (65.9%). At advanced stage, bone pain and tenderness (86.4%), anemia (70.5%), weakness of lower limbs (38.6), renal failure (29.5%), increased erythrocyte sedimentation rate (94.4%), hypercalcemia (32.2%), hyperproteinemia (60.7%), proteiuria (61.4%), hypergammaglobulinemia (78.1%), and hyperplasmocytogenesis (92.3%) were reported. 7/12 cases of immunoelectrophoresis had IgG myeloma. Demineralization and compressed vertebral fractures were found in 74.1% of patients. Other common bone lesions were observed radiographiccally in ribs (75%) and skull (72.7%)
Multiple Myeloma ; Back Pain ; diagnosis

Nodular hepatic involvement of multiple myeloma is very rare. We report here on a case of nodular hepatic involvement of multiple myeloma that mimicked intrahepatic cholangiocarcinoma. In patients with multiple myeloma, hepatic involvement of the multiple myeloma might be included in the differential diagnosis of hepatic mass.
Cholangiocarcinoma* ; Diagnosis, Differential ; Humans ; Liver* ; Multiple Myeloma*

Nodular hepatic involvement of multiple myeloma is very rare. We report here on a case of nodular hepatic involvement of multiple myeloma that mimicked intrahepatic cholangiocarcinoma. In patients with multiple myeloma, hepatic involvement of the multiple myeloma might be included in the differential diagnosis of hepatic mass.
Cholangiocarcinoma* ; Diagnosis, Differential ; Humans ; Liver* ; Multiple Myeloma*

Diagnostic Imaging ; Humans ; Multiple Myeloma ; diagnosis ; therapy

Humans ; Multiple Myeloma ; diagnosis ; therapy ; Prognosis

OBJECTIVE: To explore the expression of CD28 in multiple myeloma and its correlation with tumor burden and clinical prognosis. METHODS: Flow cytometry was adopted to analyze bone marrow specimens of 91 newly diagnosed patients with multiple myeloma. According to CD28 expression, the patients were divided into CD28⁺ group and CD28^- group, and the differences between the two groups in clinical features, genetic abnormalities, and treatment response were compared. Staging was carried out in accordance with the International Staging System (ISS). RESULTS: Among 91 newly diagnosed patients, there were 31 cases in CD28⁺ group and 60 cases in CD28^- group. The proportion of ISS-Ⅲ patients in the CD28⁺ group was 70.97%, which was higher than 50.00% in the CD28^- group (P<0.05). The median of bone marrow plasma cells in the CD28⁺ group was 41.78(2.00-77.00), which was higher than 26.92(2.00-92.00) in the CD28^- group (P<0.05). β₂-microglobulin level in the CD28⁺ group was 6.53(2.11-36.50) mg/L, which was higher than 5.76(2.00-31.34) mg/L in the CD28^- group (P<0.05). The positive rate of poor karyotype in the CD28⁺ group was 70.00% (21/30), which was higher than 45.00% (27/60) in the CD28^- group (P=0.025). After 4 cycles of chemotherapy, the total effective rate of CD28^- group was 86.27%, which was higher than 60.00% of CD28⁺ group (P<0.05). After a median follow-up of 10 months, the progression-free survival (PFS) time of CD28⁺ group was 10.7 months, which was lower than 14 months of CD28^- group (P<0.05). Univariate analysis showed that age ≥ 65 years old, hemoglobin < 60 g/L, ISS-III, CD28⁺ expression and ≥ 2 genetic abnormalities were not risk factors for PFS, while further multivariate analysis showed that induction effect < partial response (PR) and CD28⁺ expression and were independent risk factors for PFS. CONCLUSION CD28⁺ is associated with clinical characteristics and prognosis of newly diagnosed multiple myeloma patients, and can be used as a reference index to evaluate the prognosis.
Humans ; Aged ; Multiple Myeloma/diagnosis* ; Clinical Relevance

Diagnosis, Differential ; Humans ; Multiple Myeloma ; Plasma Cells

Aged ; Colonic Neoplasms ; diagnosis ; Humans ; Lung Neoplasms ; diagnosis ; Male ; Multiple Myeloma ; diagnosis ; Neoplasms, Multiple Primary ; diagnosis

This review focuses on the clinical use of (18)F-FDG PET to evaluate multiple myeloma. (18)F-FDG PET is useful for diagnosis, staging of multiple myeloma and differential diagnosis of myeloma related disease such as monoclonal gammopathy of undetermined significance or plasmacytoma. For therapy response, (18)F-FDG PET may be effective after chemotherapy for multiple myeloma and radiotherapy for plasmacytoma.
Diagnosis, Differential ; Monoclonal Gammopathy of Undetermined Significance ; Multiple Myeloma ; Plasmacytoma